Reinitiation of Anticoagulation After Temporary Withdrawal of Vitamin K Antagonist (DOSIDO)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
It is not known how to best restart warfarin after temporary withdrawal. Participants will be randomized to two groups. Group 1 will restart warfarin at their usual maintenance dose, group 2 will restart warfarin at double their maintenance dose for two days followed by their usual maintenance dose. The main outcome parameter will be the number of patients who are back in therapeutic INR (international normalized ratio) range 4, and 9 days after restarting anticoagulation with warfarin. Thromboembolic and/or bleeding events will be recorded as additional parameters. These data will be collected by a standardized telephone interview at 1 month. In addition, the investigators will evaluate a possible prothrombotic state by measuring the potential of thrombin generation and D-dimers in the subset of patients visiting HHS-General Hospital for their INR tests.
| Condition | Intervention | Phase |
|---|---|---|
|
Atrial Fibrillation Venous Thromboembolism Heart Valve Disease Surgery |
Drug: Double dose |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase II Study of Double Versus Single Reinitiation Dose of Warfarin After Interruption for Surgery |
- Proportion of patients with INR back in therapeutic range Day 5 or Day 10 [ Time Frame: Day 5-10 ] [ Designated as safety issue: No ]Proportion of patients with INR 2.0-3.0 on Day 5 or Day 10 (day of invasive procedure defined as Day 1)
- Thromboembolic events [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]Objectively verified arterial or venous thromboembolic events
- Major bleeding events [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]Defined by the ISTH criteria of 2010
- Minor bleeding events [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]Any bleeding requiring medical attention but not fulfilling the criteria of Major bleeding
- Laboratory parameters of hypercoagulability [ Time Frame: 10 days ] [ Designated as safety issue: Yes ]Quantitative D-dimer and Thrombin Generation performed in a subset at day of procedure, day 5 and 10 to identify abnormal rise.
| Estimated Enrollment: | 104 |
| Study Start Date: | April 2011 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Double dose
Re-initiation with warfarin at twice the usual maintenance dose the first 2 days, then maintenance dose.
|
Drug: Double dose
For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
Other Name: Loading dose
|
|
No Intervention: Usual maintenance dose
Usual maintenance dose from Day 1, i.e. no postoperative loading dose.
|
Detailed Description:
We will investigate if it is feasible to use double maintenance dose for the first two administrations of vitamin K antagonists when these drugs were temporarily interrupted and thus keep the time of an increased risk of thromboembolism and duration of "bridging" at a minimum. The control group will consist of patients who resume vitamin K antagonists at their usual maintenance dose. The aim of the study is to establish how to best restart anticoagulation with vitamin K antagonists after temporal withdrawal of these drugs. The main outcome parameter will be the proportion of patients who are back to a therapeutic international normalized ratio (INR) ratio at certain days after restarting vitamin K antagonists. Two additional parameters will be evaluated: Firstly, bleeding and thromboembolic complications will be reported and secondly, a possible prothrombotic state, measured as an elevation of D-dimer, at the initiation of anticoagulation will be evaluated.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Current treatment with warfarin
- Need for temporary interruption for invasive procedure or surgery
Exclusion Criteria:
- Need for post-operative hospitalization more than one day
- Participation in another clinical trial
- No consent given
Contacts and Locations| Contact: Sam Schulman, MD | 1-905-5270271 ext 44810 | schulms@mcmaster.ca |
| Canada, Ontario | |
| Thrombosis Service, HHS- General Hospital | Recruiting |
| Hamilton, Ontario, Canada, L8L 2X2 | |
| Contact: Sam Schulman, MD, PhD 1-905-5270271 ext 44810 schulms@mcmaster.ca | |
| Contact: Jennifer Delaney, RN 1-905-5270271 ext 44510 delaneyj@hhsc.ca | |
| Sub-Investigator: Hun-Gyu Hwang, MD | |
| Principal Investigator: | Sam Schulman, MD, PhD | McMaster University |
More Information
Publications:
| Responsible Party: | Sam Schulman, Prof., McMaster University |
| ClinicalTrials.gov Identifier: | NCT01348074 History of Changes |
| Other Study ID Numbers: | HGH20090520 |
| Study First Received: | May 3, 2011 |
| Last Updated: | July 24, 2012 |
| Health Authority: | Canada: Health Canada |
Keywords provided by McMaster University:
|
warfarin surgery management thromboembolism bleeding |
Additional relevant MeSH terms:
|
Atrial Fibrillation Heart Valve Diseases Thromboembolism Venous Thromboembolism Venous Thrombosis Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |
Embolism and Thrombosis Vascular Diseases Thrombosis Warfarin Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013